Patents Examined by Savitha Rao
  • Material and methods for treating developmental disorders including comorbid and idiopathic autism
    Patent number: 9463172
    Abstract: The present invention is directed to a method of treating a subject with autism spectrum disorder by administering an acetylaminopropane sulfonate.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: October 11, 2016
    Assignee: Indiana University Research & Technology Corporation
    Inventor: Craig A. Erickson
  • Selective inhibition of ?1-adrenergic receptors for the treatment of pediatric heart failure
    Patent number: 9456997
    Abstract: Provided are methods of treating heart failure in children using B1-selective adrenergic receptor antagonists, alone or in combination with other agents, including B-2-selective adrenergic receptor agonists.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: October 4, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Brian Stauffer, Carmen Sucharov, Shelley Miyamoto
  • Anise flavored medication
    Patent number: 9457085
    Abstract: An anise flavored liquid medication. The liquid medication contains phenylephrine and an anethole analog that is substantially free of aldehyde groups. In one example, the anethole analog can be 1-methoxy-4-n-propylbenzene.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: October 4, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Allyn Michael Kaufmann, James Carl Grimm, Chelsay Lynn Brewster, Thomas Edward Huetter
  • Fungicidal composition comprising mancozeb and chlorothalonil
    Patent number: 9451769
    Abstract: Disclosed herein is a fungicidal composition comprising combination of fungicidally effective amount of mancozeb and a fungicidally effective amount of chlorothalonil in a predetermined ratio.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: September 27, 2016
    Assignee: UPL Limited
    Inventors: Jaidev Rajnikant Shroff, Vikram Rajnikant Shroff, Philip Wayne Robinson, Beth Errickson Sears, Prakash Mahadev Jadhav
  • Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
    Patent number: 9446127
    Abstract: The present invention includes methods and compositions useful for treating and preventing skin disorders, hair loss and other skin disorders. The compositions include an ARD enhancer in combination with a second compound or composition. In some embodiments the second compound is at least one of a bactericide, an antibiotic, an anti-microbial peptide, Vitamin A, a Vitamin A derivative, a retinoid, an anti-inflammatory compound, and anti-androgen compounds.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: September 20, 2016
    Assignee: AndroScience Corporation
    Inventors: Charles C. Y. Shih, Ching-Yuan Su, Hui-Kang Wang, Qian Shi
  • Methods for treating leukemia and disorders mediated by CBF? and RUNX1 proteins
    Patent number: 9446048
    Abstract: A method for treating core binding factor (CBF) leukemia in a subject, comprising administering to a subject having CBF leukemia a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, that inhibits CBF? and RUNX1 binding in the subject, thereby treating the CBF leukemia.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: September 20, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Pu Liu, Wei Zheng, Juan Marugan, Noel T. Southall, Lea Cunningham
  • Use of metallocene compounds for cancer treatment
    Patent number: 9441000
    Abstract: Metallocene compounds and pharmaceutical compositions containing these metallocene compounds are disclosed and described. Methods of treating cancer employing such metallocene compounds and pharmaceutical compositions also are provided.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: September 13, 2016
    Assignee: Chevron Philips Chemical Company, LP
    Inventors: Mark L. Hlavinka, Qing Yang, Mandi Michelle Murph
  • Non-hormonal steroid modulators of NF-?B for treatment of disease
    Patent number: 9434758
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: September 6, 2016
    Assignee: ReveraGen Biopharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Sulfonamides as TRPM8 modulators
    Patent number: 9434711
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 6, 2016
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shawn T Branum, Raymond W Colburn, Scott L Dax, Christopher M Flores, Michele C Jetter, Yi Liu, Donald Ludovici, Mark J Macielag, Jay M Matthews, James J McNally, Laura M Andraka, Ronald K Russell, Ning Qin, Christopher Teleha, Kenneth M Wells, Scott C Youells, Mark A Youngman
  • Narcotic emulsion formulations for treatment of cancer pain
    Patent number: 9427435
    Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 30, 2016
    Assignees: Teikoku Pharma USA, Inc., Techno Guard Co., Ltd.
    Inventors: Kiichiro Nabeta, Toru Hibi
  • Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
    Patent number: 9427401
    Abstract: Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: August 30, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Wha-Bin Im, Robert M. Burk
  • Thiazolamine derivative and use thereof as anti-picornaviral infection medicament
    Patent number: 9428496
    Abstract: Disclosed is as a substituted thiazolamine derivative represented by Formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof (the definitions of each group in the formula are as presented in the description), and the application thereof in the prevention and/or treatment of viral diseases induced by picornavirus. Also disclosed is a pharmaceutical composition containing the compound.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: August 30, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Hongliang Wang, Junhai Xiao, Xian Zhang, Lili Wang, Zhibing Zheng, Wu Zhong, Yunde Xie, Xingzhou Li, Xinbo Zhou, Guoming Zhao, Xiaokui Wang
  • Methods of treatment using a BCAT1 inhibitor
    Patent number: 9422224
    Abstract: The present invention is directed to BCAT inhibitors with the following formula: Wherein R1 is a linear alkyl group and X+ denotes a cation. These inhibitors are useful in treating autoimmune inflammatory diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: August 23, 2016
    Assignee: ERGON PHARMACEUTICALS LLC
    Inventor: Adonia E. Papathanassiu
  • Compounds and methods for treating diseases mediated by protease activated receptors
    Patent number: 9422262
    Abstract: The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: August 23, 2016
    Assignees: The Broad Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Chris Dockendorff, Robert Flaumenhaft
  • Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
    Patent number: 9408816
    Abstract: Provided herein are methods for using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity, methods for monitoring the decrease of cellular DNA repair activity using at least one biomarker, methods of treating cancer by using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity in combination therapy, methods of combination therapy where at least one histone deacetylase inhibitor interferes with a DNA repairing mechanism involving RAD51, methods for predicting a induction time period between a first administration of at least one histone deacetylase inhibitor and a second administration of at least one other therapeutic treatment, and pharmaceutical compositions for combination therapy.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: August 9, 2016
    Assignee: Pharmacyclics LLC
    Inventors: Shanthi Adimoolam, Joseph J. Buggy, Darren Magda, Richard Miller
  • Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer
    Patent number: 9402846
    Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: August 2, 2016
    Assignee: Novartis AG
    Inventors: Melissa Dumble, Tona Gilmer, Rakesh Kumar, Sylvie Laquerre, Peter F. Lebowitz, Shannon Renae Morris
  • Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics
    Patent number: 9403769
    Abstract: Small molecule inhibitors of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) having the following formula: Formula (1) are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting PFK.FB3 enzymatic activity, methods of inhibiting glycolytic flux, and methods of treating tumors by administering an effective amount of a Formula I compound.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: August 2, 2016
    Assignees: Advanced Cancer Therapeutics, LLC, University of Louisville Research Foundation, Inc.
    Inventors: Pooran Chand, Jason A. Chesney, Brian F. Clem, Gilles H. Tapolsky, Sucheta Telang, John O. Trent
  • Benzothiophene compound
    Patent number: 9399038
    Abstract: A method for preventing or treating a disease selected from the group consisting of visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia in a subject in need thereof, comprising administering to said subject an effective amount of the compound of the following formula (I) or a salt thereof: wherein R1, R2, R3, R4, R5, X and n are as described herein.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: July 26, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Tsukasa Ishihara, Kazuhiro Ikegai, Ikumi Kuriwaki, Hiroyuki Hisamichi, Nobuaki Takeshita, Ryuichi Takezawa
  • Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
    Patent number: 9394239
    Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 19, 2016
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
    Patent number: 9387208
    Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of the formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: July 12, 2016
    Assignee: Novartis AG
    Inventors: Daya Verma, Yogita Krishnamachan, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan